T-cell dysfunction in natural killer/T-cell lymphoma

Xiaoyan Feng(Academy of Military Medical Sciences), Mingzhi Zhang(Soochow University)

OncoImmunology

May 24, 2023

10.1080/2162402x.2023.2212532

Cited by 14

Related Papers

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|246

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

|Journal of Hematology & Oncology|2020|50

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma

|Nature Communications|2019|34

<p>Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-&gamma;-associated JAK-STAT pathway</p>

|OncoTargets and Therapy|2019|31

ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells <i>in vitro</i>

|Oncotarget|2015|24